Novacyt S.A (ALNOV) | Financial Analysis & Statements
Novacyt S.A. | Small-cap | Healthcare
Novacyt S.A. | Small-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
19.6M
Gross Profit
32.1M
163.39%
Operating Income
-16.7M
-84.87%
Net Income
-41.8M
-212.73%
EPS (Diluted)
-€0.59
Balance Sheet Metrics
Total Assets
70.6M
Total Liabilities
22.8M
Shareholders Equity
47.9M
Debt to Equity
0.48
Cash Flow Metrics
Operating Cash Flow
-7.6M
Free Cash Flow
-11.0M
Revenue & Profitability Trend
Novacyt S.A Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 19.6M | 10.6M | 21.0M | 92.6M | 277.2M |
| Cost of Goods Sold | -12.4M | 7.1M | 15.3M | 64.4M | 65.7M |
| Gross Profit | 32.1M | 3.5M | 5.7M | 28.2M | 211.5M |
| Operating Expenses | 44.7M | 16.8M | 10.6M | 12.6M | 7.8M |
| Operating Income | -16.7M | -15.8M | -15.7M | 1.4M | 174.9M |
| Pre-tax Income | -39.4M | -24.5M | -20.1M | -5.7M | 165.2M |
| Income Tax | -732.0K | -353.0K | 2.1M | 349.0K | 32.7M |
| Net Income | -41.8M | -28.3M | -25.7M | -9.7M | 132.4M |
| EPS (Diluted) | -€0.59 | -€0.40 | -€0.36 | -€0.14 | €1.94 |
Income Statement Trend
Novacyt S.A Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 39.4M | 86.4M | 127.2M | 158.8M | 205.0M |
| Non-Current Assets | 31.3M | 47.4M | 13.7M | 24.9M | 29.3M |
| Total Assets | 70.6M | 133.8M | 140.9M | 183.7M | 234.3M |
| Liabilities | |||||
| Current Liabilities | 6.2M | 29.6M | 24.2M | 38.9M | 74.1M |
| Non-Current Liabilities | 16.5M | 17.0M | 1.4M | 3.0M | 9.4M |
| Total Liabilities | 22.8M | 46.6M | 25.7M | 41.9M | 83.6M |
| Equity | |||||
| Total Shareholders Equity | 47.9M | 87.2M | 115.2M | 141.8M | 150.7M |
Balance Sheet Composition
Novacyt S.A Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -41.8M | -28.3M | -25.7M | -9.7M | 132.4M |
| Operating Cash Flow | -7.6M | -21.7M | -4.9M | 51.4M | 25.6M |
| Investing Activities | |||||
| Capital Expenditures | -1.3M | -491.0K | -156.0K | -3.8M | -1.0M |
| Investing Cash Flow | -2.4M | -15.9M | -955.0K | -4.7M | -7.8M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 116.0K | -2.0M | -13.0K | -29.0K | -4.2M |
| Free Cash Flow | -11.0M | -23.0M | -14.1M | 11.6M | 101.8M |
Cash Flow Trend
Novacyt S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-0.82
Forward P/E
1.88
Price to Book
0.72
Price to Sales
1.78
PEG Ratio
1.88
Profitability Ratios
Profit Margin
-212.73%
Operating Margin
-84.87%
Return on Equity
-57.28%
Return on Assets
-10.19%
Financial Health
Current Ratio
6.33
Debt to Equity
24.81
Beta
0.12
Per Share Data
EPS (TTM)
-€0.64
Book Value per Share
€0.68
Revenue per Share
€0.28
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| alnov | 34.9M | -0.82 | 0.72 | -57.28% | -212.73% | 24.81 |
| Eurobio Scientific | 253.4M | 64.74 | 1.42 | 2.26% | 2.58% | 5.46 |
| Affluent Medical | 53.3M | -3.55 | 1.73 | -48.69% | -275.50% | 0.54 |
| Carmat S.A | 24.8M | - | - | 100.52% | -336.56% | -1.13 |
| Median Technologies | 25.6M | -1.02 | - | 74.31% | -109.93% | -0.98 |
| Diagnostic Medical | 24.2M | -8.64 | 1.96 | -20.20% | -5.90% | 141.76 |
Financial data is updated regularly. All figures are in the company's reporting currency.